MDxHealth SA is a company with limited liability (naamloze vennootschap/société anonyme) incorporated and operating under the laws of Belgium.
Company profile
Ticker
MDXH
Exchange
Employees
Incorporated
Location
Industry (SIC)
Former names
MDx Health SA
SEC CIK
Latest filings (excl ownership)
6-K
Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering
12 Mar 24
6-K
Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results
6 Mar 24
6-K
Mdxhealth Announces Resignation of Board Member
16 Feb 24
6-K
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2023 Revenues
8 Jan 24
6-K
MDxHealth Announces Completion of Transition to Single Listing on Nasdaq
19 Dec 23
6-K
MDxHealth Announces Completion of Mandatory ADS Exchange and Commencement of Transition Period to Single Listing on Nasdaq
27 Nov 23
8-A12B/A
Registration of securities on exchange (amended)
24 Nov 23
25-NSE
Exchange delisting
24 Nov 23
6-K
Report of Foreign Private Issuer
15 Nov 23
6-K
MDxHealth Announces Completion of Share Consolidation, and Update of Outstanding Shares and Voting Rights
13 Nov 23
Transcripts
Latest ownership filings
SC 13G/A
Bleichroeder LP
14 Feb 24
SC 13D/A
TopMDx Ltd.
14 Apr 23
SC 13G/A
Biovest NV
17 Mar 23
4
Change in insider ownership
28 Feb 23
SC 13D/A
MVM Partners, LLC
28 Feb 23
SC 13G/A
Bleichroeder LP
14 Feb 23
SC 13D/A
MVM Partners, LLC
23 Nov 22
SC 13G
Biovest NV
14 Feb 22
SC 13G/A
Bleichroeder LP
14 Feb 22
SC 13D
MVM Partners LLP
27 Dec 21
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Institutional ownership, Q2 2022
77.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 4 |
Opened positions | 1 |
Closed positions | 2 |
Increased positions | 1 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 242.77 mm |
Total shares | 21.08 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
TopMDx | 19.03 mm | $225.66 mm |
Bleichroeder | 1.96 mm | $16.35 mm |
Perkins Capital Management | 90.46 k | $755.00 k |
Castle Wealth Management | 60.00 | $1.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
3 Feb 23 | MVM Partners | Common Stock | Buy | Acquire P | Yes | No | 4 | 1,000,000 | 4.00 mm | 45,504,584 |
News
Mdxhealth Adds Hereditary Prostate Cancer Genetic Test To Prostate Cancer Offering
12 Mar 24
These Analysts Increase Their Forecasts On MDxHealth After Q4 Results
7 Mar 24
Piper Sandler Maintains Overweight on MDxHealth, Raises Price Target to $7
7 Mar 24
BTIG Maintains Buy on MDxHealth, Raises Price Target to $8
7 Mar 24
MDxHealth Q4 2023 GAAP EPS $(0.390) Misses $(0.150) Estimate, Sales $19.398M Beat $18.136M Estimate
6 Mar 24
Press releases
Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering
12 Mar 24
Mdxhealth Announces Fourth Quarter and Full-Year 2023 Financial Results
6 Mar 24
MDxHealth to Present Fourth Quarter and Full Year 2023 Financial Results and Corporate Update on March 6
21 Feb 24
Mdxhealth Announces Resignation of Board Member
16 Feb 24